What is the Share Price of Balaxi Pharmaceuticals Ltd?

Balaxi Pharmaceuticals Ltd share price is ₹113.93 As on 17 September, 2024|17:59

Home
>
Stocks
>
Balaxi Pharmaceuticals Ltd

Balaxi Pharmaceuticals Ltd

Q: What is the Market Cap of Balaxi Pharmaceuticals Ltd?

The Market Cap of Balaxi Pharmaceuticals Ltd is ₹609 As on 17 September, 2024|17:59

Q: What is PE Ratio of Balaxi Pharmaceuticals Ltd?

The P/E ratio of Balaxi Pharmaceuticals Ltd is 16.5 As on 17 September, 2024|17:59

Q: What is PB Ratio of Balaxi Pharmaceuticals Ltd?

The PB ratio of Balaxi Pharmaceuticals Ltd is 3.14 As on 17 September, 2024|17:59

₹ 113.93 +4.06 (3.70%)
Updated on 17-09-2024 4:40 PM

Stock Rating

NSE

Pros 4

Cons 2

Price Performance

Day's Low
₹111

Day's High
₹114.65

₹ 113.93

52-w low
₹79.99

52-w high
₹151.45

113.93

Day's open
₹111
Previous close
₹109.870003
VWAP
₹113.44
Lower price band
₹87.89
Upper price band
₹131.84

Today's Market Action

The last traded share price of Balaxi Pharmaceuticals Ltd was 113.93 up by 3.70% on the NSE. The total volume of shares on NSE and BSE combined was 91,890 shares. Its total combined turnover was Rs 1.04 crores.

Medium and Long Term Market Action

Balaxi Pharmaceuticals Ltd hit a 52-week high of 151.45 on 30-05-2024 and a 52-week low of 79.99 on 31-10-2023. The stock price of Balaxi Pharmaceuticals Ltd is up by 4% over the last one month. Don't forget to check the full stock price history in the table below.

Fundamentals

Market Cap (Cr): 609
Book Value (₹):
Stock P/E:
Revenue (Cr):
Total Debt (Cr):

Face Value (₹):
Roce (%):
ROE (%):
Earnings (Cr):
Promoter’s Holdings (%):

EPS (₹):
Debt to Equity:
Dividend Yield (%):
Cash (Cr):

Mutual fund holdings and trends

FUND NAME	Quantity	Monthly Change (Qty)

Shareholding Pattern

Similar Stocks

Company	Price	Market Cap (Cr)	P/E

About

Data not available.

FAQ's

What is Share Price of Balaxi Pharmaceuticals Ltd?

What is the Market Cap of Balaxi Pharmaceuticals Ltd?

What is PE Ratio of Balaxi Pharmaceuticals Ltd?

What is PB Ratio of Balaxi Pharmaceuticals Ltd?

What is the CAGR of Balaxi Pharmaceuticals Ltd?

How to Buy Balaxi Pharmaceuticals Ltd Share?

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

Pros

Above Average Sustainable RoE
The company generates a sustainable return on equity greater than the expected cost of capital which implies that the underlying business can create and compound value over a period time due to it's ability to generate above average return on capital.
Great Cash Conversion of Profits
The business has a great cash conversion ratio since it is able to convert a signifant portion of operating earnings of 71.43% into operating cash flow. This implies a great working capital cycle and large cash flows for either funding growth or dividends. This shall positively impact shareholder returns.
Asset Light Business
The company operates a great asset light business with a high Asset turnover ratio of 5.60. A high asset turnover ratio is a great driver of RoE and can improve shareholder returns. A relatively higher asset turnover ratio also will result in lower dilution as the business grows its revenues as earnings.
Zero Debt
The company has almost nil to negligible debt to equity ratio of 0.10. Considering the fact that the business is debt free, equity shareholders shall carry lower risk of holding the stock.

Cons

Poor Capital Allocation
The company has disproportionately high amount of assets locked up in working capital, cash and cash equivalents, loans and advances, etc to the extent of 83.33 % of total assets. This reflects poorly on the capital allocation strategy of the management which negatively impacts shareholder returns.
Poor Working Capital Cycle
The company has a very poor working capital cycle of 209 days which requires very high investments in working capital. This reduces free cash flow generation for the business and negatively impacts shareholder value and returns.

Valuation Analysis

Margin of safety
(17/09/2024)

101

Margin of Safety Index: High

0% People are bullish about Balaxi Pharmaceuticals Ltd

0 % People are bearish about Balaxi Pharmaceuticals Ltd

What is your opinion about this Stock?

Historical Data

Date	Open	High	Low	Close	Volume	Daily Change %